The 2025 Investment Day | 2025 Family Office Summits | Family Office Circle
Investment / Alternatives Summit - March / Oct / Nov
Investment Day - March / July / Sept / Oct / Nov
Private Wealth Summit - April / Oct / Nov
Family Office Summit - April / Oct / Nov
View Events | Register
This site is for accredited investors, professional investors, investment managers and financial professionals only. You should have assets around $3 million to $300 million or managing $20 million to $30 billion.
United States SEC Fines $65 Billion Medical Device Manufacturer Becton, Dickinson & Co $175 Million for Repeatedly Misleading Investors on Risks of Continued Sales of Alaris Infusion Pump for Patients & Overstating Income by Failing to Record Software Fixing Costs in 2019 & Early 2020
18th December 2024 | Hong Kong
The United States Securities & Exchange Commission (SEC) has fined medical device manufacturer Becton, Dickinson & Co ($65 billion market value) $175 million for repeatedly misleading investors on risks of continued sales of Alaris infusion pump for patients & overstating income by failing to record software fixing costs in 2019 & early 2020. United States SEC (16/12/24): “The Securities and Exchange Commission today announced settled charges against Becton, Dickinson and Company, a New Jersey-based medical device manufacturer known as BD, for repeatedly misleading investors about risks associated with its continued sales of its Alaris infusion pump and for overstating its income by failing to record the costs of fixing multiple software flaws with the pump. BD agreed to pay a $175 million civil penalty. According to the SEC’s order, BD determined in 2016 that software changes made to the Alaris pump required regulatory clearance from the Food and Drug Administration (FDA). However, BD did not have the data required for clearance, and generating the data would delay the release of new features, so BD continued selling the pump without clearance. By January 2019, BD identified more than 25 flaws in the pump’s software that its experts categorized as presenting risks of the greatest potential harm to patients. Rather than inform investors that these issues heightened the risk that the FDA would limit BD’s ability to continue selling Alaris—a product whose sales contributed about 10 percent of BD’s profits—BD made misleading statements in its periodic reports about its regulatory risks. The order finds that BD revealed Alaris’s software flaws to the FDA in October 2019 and proposed that the agency allow it to continue selling the pump while it worked to fix the flaws and complete the lengthy FDA clearance process. The FDA firmly rejected this proposal so BD immediately stopped shipping Alaris. But several days later, BD decided it would resume shipping the pump after fixing its software flaws – without FDA clearance. During an earnings call in early November 2019, BD misleadingly told investors that it was pausing Alaris sales to make “some improvements” to the pump as part of its strategy to “continually iterate and make enhancements to the platform.” BD also made financial forecasts for fiscal year 2020 without warning investors that those forecasts were based on conjecture that the FDA would allow BD to resume sales of Alaris without clearance. The order finds that, in mid-November, BD changed its plan; it would resume shipping Alaris with a new version of the software that would exclude fixes that required FDA clearance. This meant BD would not fix several flaws the FDA had expressed significant concerns about, making it even less likely that the agency would allow BD to fully resume Alaris sales. Nevertheless, during subsequent investor conferences in November and December 2019, BD echoed its prior misleading statements. The order finds that BD resumed shipping Alaris with the new software in December 2019 without any indication from the FDA that it concurred with this approach. After the FDA learned in January 2020 what BD had done, the agency warned that BD’s decision to resume selling Alaris was “misaligned with our previous conversations regarding your software issues and our mutual agreement that your firm should not be distributing devices to new customers.” BD reinstated the ship hold and understood there would likely be a materially negative impact on the company’s revenue in fiscal year 2020. Nevertheless, during its subsequent annual shareholders meeting in late January 2020, BD again reaffirmed its prior fiscal year 2020 revenue guidance. BD finally told investors in February 2020 that it had ceased shipping Alaris and would not resume normal sales until it had completed the lengthy FDA clearance process. Its share price subsequently declined 12 percent. Following the announcement, one analyst texted a senior member of BD’s investor relations group, “I do not understand what happened here. 10 days ago we heard everything in pumps was ok and back on market and better than expected . . . I’m stunned and have a lot of angry people with pitchforks … … The SEC’s order finds that BD materially overstated its operating income in FY2019 by failing to properly account for the costs of remediating Alaris to fix the software flaws, resulting in the company overstating its operating income in the fourth quarter of fiscal year 2019 by 82 percent. The SEC’s order finds that BD violated antifraud, reporting, internal accounting controls, books and records, and disclosure controls provisions of the federal securities laws. Without admitting or denying the SEC’s findings, BD agreed to cease and desist from further violations of these provisions, to retain an independent compliance consultant to review and make recommendations concerning its disclosure controls and procedures, and to the civil penalty referenced above.”
“ United States SEC Fines $65 Billion Medical Device Manufacturer Becton, Dickinson & Co $175 Million for Repeatedly Misleading Investors on Risks of Continued Sales of Alaris Infusion Pump for Patients & Overstating Income by Failing to Record Software Fixing Costs in 2019 & Early 2020 “
Caproasia Access | Events | Summits | Register Events | The Financial Centre
The 2025 Investment Day | 2025 Family Office Summits | Family Office Circle
Basic Member: $5 Monthly | $60 Yearly
Newsletter Daily 2 pm (Promo): $20 Monthly | $180 Yearly (FP: $680)
Hong Kong | Singapore
March / July / Sept / Oct / Nov
Private Equity, Hedge Funds, Boutique Funds, Private Markets & more. Join 20+ CIOs & Senior investment team, with > 60% single family offices with $300 million AUM. Taking place in Hong Kong and in Singapore. Every March, July, Sept, Oct & Nov.
Visit | Register here
10th April & 16th Oct Hong Kong Ritz Carlton | 24th April & 6th Nov Singapore Amara Sanctuary Resort
Join 80 single family offices & family office professionals in Hong Kong & Singapore
Links: 2025 Family Office Summit | Register here
March / Oct / Nov in Hong Kong & Singapore
Join leading asset managers, hedge funds, boutique funds, private equity, venture capital & real estate firms in Hong Kong, Singapore & Asia-Pacific at the Investment / Alternatives Summit. Join as delegate, speaker, presenter, partner & sponsor.
Visit | Register here
April / Oct / Nov in Hong Kong & Singapore
Join CEOs, CIOs, Head of Private Banking, Head of Family Offices & Product Heads at The Private Wealth Summit. Join as delegate, speaker, presenter, partner & sponsor.
Visit | Register here
United States SEC Fines $65 Billion Medical Device Manufacturer Becton, Dickinson & Co $175 Million for Repeatedly Misleading Investors on Risks of Continued Sales of Alaris Infusion Pump for Patients & Overstating Income by Failing to Record Software Fixing Costs in 2019 & Early 2020
For Investment Managers, Hedge Funds, Boutique Funds, Private Equity, Venture Capital, Professional Investors, Family Offices, Private Bankers & Advisors, sign up today. Subscribe to Caproasia and receive the latest news, data, insights & reports, events & programs daily at 2 pm.
Join Events & Find Services
Join Investments, Private Wealth, Family Office events in Hong Kong, Singapore, Asia-wide. Find hard-to-find $3 million to $300 million financial & investment services at The Financial Centre | TFC. Find financial, investment, private wealth, family office, real estate, luxury investments, citizenship, law firms & more. List hard-to-find financial & private wealth services.
Have a product launch? Promote a product or service? List your service at The Financial Centre | TFC. Join interviews & editorial and be featured on Caproasia.com or join Investments, Private Wealth, Family Office events. Contact us at angel@caproasia.com or mail@caproasia.com
Caproasia.com | The leading source of data, research, information & resource for financial professionals, investment managers, professional investors, family offices & advisors to institutions, billionaires, UHNWs & HNWs. Covering capital markets, investments and private wealth in Asia. How do you invest $3 million to $300 million? How do you manage $20 million to $3 billion of assets?
The 2025 Investment Day | 2025 Family Office Summits | Family Office Circle
2020 List of Private Banks in Hong Kong
2020 List of Private Banks in Singapore
2020 Top 10 Largest Family Office
2020 Top 10 Largest Multi-Family Offices
2020 Report: Hong Kong Private Banks & Asset Mgmt - $4.49 Trillion
2020 Report: Singapore Asset Mgmt - $3.48 Trillion AUM
For Investors | Professionals | Executives
Latest data, reports, insights, news, events & programs
Everyday at 2 pm
Direct to your inbox
Save 2 to 8 hours per week. Organised for success
Register Below
Get Ahead in 60 Seconds. Join 10,000 +
Save 2 to 8 hours weekly. Organised for Success.
Sign Up / Register
Please click on desktop.
Caproasia Users
- Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2025 Investment Day
- March - Hong Kong
- March - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
Contact Us
For Enquiries, Membershipmail@caproasia.com, angel@caproasia.com
For Listing, Subscription
mail@caproasia.com, claire@caproasia.com
For Press Release, send to:
press@caproasia.com
For Events & Webinars
events@caproasia.com
For Media Kit, Advertising, Sponsorships, Partnerships
angel@caproasia.com
For Research, Data, Surveys, Reports
research@caproasia.com
For General Enquiries
mail@caproasia.com
a financial information technology co.
since 2014
